Acrivon Therapeutics (ACRV) Institutional Ownership → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ACRV Stock Alerts $7.15 +0.69 (+10.68%) (As of 03/28/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Acrivon Therapeutics (NASDAQ:ACRV)CurrentInstitutional OwnershipPercentage71.62%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$14.29 MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$3.64 M Get ACRV Insider Trade Alerts Want to know when executives and insiders are buying or selling Acrivon Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACRV Institutional Buying and Selling by Quarter Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> Acrivon Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/11/2024Vanguard Group Inc.475,977$2.34M0.0%+1.6%2.145% 2/15/2024Barclays PLC24,484$0.12M0.0%+73.6%0.110% 2/15/2024Vanguard Group Inc.475,977$2.34M0.0%+1.6%2.145% 2/15/2024Bridgeway Capital Management LLC31,981$0.16M0.0%N/A0.144% 2/13/2024Northern Trust Corp80,149$0.39M0.0%+10.2%0.361% 1/5/2024 Exchange Traded Concepts LLC13,289$65K0.0%+34.0%0.060% Get the Latest News and Ratings for ACRV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/18/2023Vanguard Group Inc.468,407$4.48M0.0%+16.2%2.111% 11/13/2023Northern Trust Corp72,722$0.70M0.0%+5.9%0.328% 11/13/2023 Federated Hermes Inc.226,375$2.16M0.0%-25.6%1.020% 11/8/2023Charles Schwab Investment Management Inc.67,661$0.65M0.0%+11.0%0.307% 9/21/2023Barclays PLC14,263$0.18M0.0%-16.0%0.065% 8/15/2023Wells Fargo & Company MN3,305$43K0.0%+108.1%0.015% 8/15/2023Citadel Advisors LLC1,649,646$21.38M0.0%+0.5%7.522% 8/14/2023State Street Corp125,976$1.63M0.0%+47.6%0.574% 8/14/2023Nuveen Asset Management LLC11,821$0.15M0.0%N/A0.054% 8/11/2023BlackRock Inc.533,355$6.91M0.0%+12.5%2.432% 8/11/2023Geode Capital Management LLC178,453$2.31M0.0%+1.7%0.814% 8/11/2023Northern Trust Corp68,678$0.89M0.0%-1.5%0.313% 8/10/2023AAF Wealth Management LLC10,678$0.14M0.1%N/A0.049% 8/10/2023Charles Schwab Investment Management Inc.60,958$0.79M0.0%+4.7%0.278% 8/10/2023Citigroup Inc.2,790$36K0.0%+1,281.2%0.013% 8/3/2023Barclays PLC14,263$0.18M0.0%-16.0%0.065% 8/3/2023 Bank of New York Mellon Corp24,795$0.32M0.0%+8.6%0.113% 7/20/2023 Exchange Traded Concepts LLC11,709$0.15M0.0%N/A0.053% 5/18/2023JPMorgan Chase & Co.6,630$84K0.0%N/A0.030% 5/18/2023 New York State Common Retirement Fund2,206$28K0.0%N/A0.010% 5/16/2023Susquehanna International Group LLP32,262$0.41M0.0%N/A0.147% 5/16/2023State Street Corp85,339$1.08M0.0%N/A0.389% 5/16/2023Geode Capital Management LLC175,404$2.23M0.0%N/A0.800% 5/15/2023Deutsche Bank AG5,369$68K0.0%N/A0.024% 5/12/2023BlackRock Inc.474,227$6.02M0.0%N/A2.162% 5/12/2023Bank of America Corp DE5,856$74K0.0%N/A0.027% 5/12/2023Wellington Management Group LLP888,130$11.14M0.0%-1.3%4.050% 5/12/2023Charles Schwab Investment Management Inc.58,209$0.74M0.0%N/A0.265% 5/9/2023 Bank of New York Mellon Corp22,837$0.29M0.0%N/A0.104% 5/9/2023California State Teachers Retirement System3,218$41K0.0%N/A0.015% 5/8/2023 Federated Hermes Inc.613,625$7.79M0.0%-25.5%2.798% 5/4/2023Barclays PLC16,983$0.22M0.0%+310.0%0.077% 2/16/2023HealthCor Management L.P.284,201$3.27M3.0%N/A1.360% 2/15/2023Millennium Management LLC19,639$0.23M0.0%N/A0.094% Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.2/14/2023RA Capital Management L.P.4,810,508$55.42M1.1%N/A23.028% 2/14/2023Marshall Wace LLP1,223,252$14.09M0.0%N/A5.856% 2/14/2023Two Sigma Investments LP21,534$0.25M0.0%N/A0.103% 2/13/2023Barclays PLC4,142$47K0.0%N/A0.020% 2/13/2023Sands Capital Ventures LLC1,652,605$19.04M5.2%N/A7.913% 2/10/2023NEA Management Company LLC481,677$4.44M0.2%N/A2.306% 2/8/2023UBS Group AG4,748$55K0.0%N/A0.023% 2/1/2023Bank of Montreal Can42,444$0.55M0.0%N/A0.203% (Data available from 1/1/2016 forward) ACRV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACRV shares? During the previous two years, 32 institutional investors and hedge funds held shares of Acrivon Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($55.42M), Citadel Advisors LLC ($21.38M), Sands Capital Ventures LLC ($19.04M), Marshall Wace LLP ($14.09M), Wellington Management Group LLP ($11.14M), BlackRock Inc. ($6.91M), and NEA Management Company LLC ($4.44M).Learn more on ACRV's institutional investors. What percentage of Acrivon Therapeutics stock is owned by institutional investors? 71.62% of Acrivon Therapeutics stock is owned by institutional investors. Learn more on ACRV's institutional investor holdings. Which institutional investors have been buying Acrivon Therapeutics stock? Of the 30 institutional investors that purchased Acrivon Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($4.81M), Sands Capital Ventures LLC ($1.65M), Marshall Wace LLP ($1.22M), BlackRock Inc. ($0.53M), NEA Management Company LLC ($0.48M), HealthCor Management L.P. ($0.28M), and Geode Capital Management LLC ($0.18M). How much institutional buying is happening at Acrivon Therapeutics? Institutional investors have bought a total of 9,727,987 shares in the last 24 months. This purchase volume represents approximately $112.72M in transactions. Which Acrivon Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Acrivon Therapeutics stock in the last 24 months: Federated Hermes Inc. ($0.29M), Wellington Management Group LLP ($12.02K), Barclays PLC ($5.44K), and Northern Trust Corp ($1.07K). How much institutional selling is happening at Acrivon Therapeutics? Institutional investors have sold a total of 306,243 shares in the last 24 months. This volume of shares sold represents approximately $3.64M in transactions. Related Companies: BeyondSpring Institutional Ownership Relmada Therapeutics Institutional Ownership PDS Biotechnology Institutional Ownership CytomX Therapeutics Institutional Ownership Galectin Therapeutics Institutional Ownership Nuvectis Pharma Institutional Ownership Syros Pharmaceuticals Institutional Ownership I-Mab Institutional Ownership NGM Biopharmaceuticals Institutional Ownership Emergent BioSolutions Institutional Ownership This page (NASDAQ:ACRV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.